BLSM.US BlossomHill Therapeutics, Inc. Common Stock
- Market cap
- USD 446M
- P/E
- -
- P/B
- -
- ROE
- -43.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BLSM.US undervalued?
Graham numberThe Graham number of BlossomHill Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BlossomHill Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for BlossomHill Therapeutics, Inc. Common Stock yet.
BlossomHill Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myel…
Full company profileBlossomHill Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BlossomHill Therapeutics, Inc. Common Stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | - |
| Operating Income | -36.4M | -64.0M | -96.3M |
| EBITDA | -36.1M | -63.6M | -96.2M |
| Net Income | -30.7M | -60.6M | -91.7M |
| EPS | -1.06 | -2.08 | -0.49 |
| Balance Sheet | |||
| Total Assets | 107M | 163M | 252M |
| Total Liabilities | 180M | 295M | 40.9M |
| Shareholders' Equity | -72.9M | -132M | 211M |
| Cash & Short-term Investments | 100M | 137M | 225M |
| Total Debt | 525K | 22.4M | 23.1M |
| Cash Flow | |||
| Operating Cash Flow | -31.4M | -46.9M | -88.5M |
| Capital Expenditure | 92.0K | 1.07M | 17.3K |
| Free Cash Flow | -31.5M | -48.0M | -88.5M |
| Ratios | |||
| ROE | - | - | -43.4% |
| ROA | -28.7% | -37.2% | -36.4% |
| Debt to Equity | - | - | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
BlossomHill Therapeutics, Inc. Common Stock dividends
BlossomHill Therapeutics, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns BlossomHill Therapeutics, Inc. Common Stock
- Insiders 12.71%
- Institutions 42.64%
- Public & others 44.65%
- Shares outstanding 31.8M
- Free float 17.6M
Top funds holding BLSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| JPMorgan Small Cap Growth A | 480K | 1.51% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 347K | 1.09% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 316K | 0.99% | +471.65% | Sep 2026 |
| JPMorgan Small Cap Blend A | 154K | 0.48% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 133K | 0.42% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Value I | 98.0K | 0.31% | 0.00% | Sep 2026 |
| JPMorgan US Small Company L | 84.1K | 0.26% | 0.00% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 73.7K | 0.23% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 60.0K | 0.19% | 0.00% | Sep 2026 |
| JPM US Small Cap Growth A dist USD | 52.6K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 46.9K | 0.15% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 44.7K | 0.14% | 0.00% | Sep 2026 |
| JPM US Small Cap Growth C Acc | 37.0K | 0.12% | +1.32% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 24.8K | 0.08% | 0.00% | Aug 2026 |
| JPMorgan American Ord | 24.1K | 0.08% | 0.00% | Aug 2026 |
| Strategic Advisers U.S. Total Stock | 21.9K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 20.1K | 0.06% | 0.00% | Sep 2026 |
| VALIC Company I Small Cap Value | 19.6K | 0.06% | 0.00% | Aug 2026 |
| LVIP JPMorgan Small Cap Core Standard | 17.8K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 16.1K | 0.05% | 0.00% | Sep 2026 |
BlossomHill Therapeutics, Inc. Common Stock company profile
- Company name
- BlossomHill Therapeutics, Inc. Common Stock
- Ticker
- BLSM.US
- Exchange
- USA Stocks
- Listed since
- Aug 7, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 10255 Science Center Drive, San Diego, CA, United States, 92121
- Phone
- (858) 732-3880
- Website
- bhtherapeutics.com
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
BlossomHill Therapeutics, Inc. Common Stock management
10- Dr. Yishan Li M.B.A., Ph.D.Co-Founder & Executive Chairman · born 1965
- Dr. Jingrong Jean Cui Ph.D.Scientific Founder, President, CEO & Director · born 1963
- Mr. Jason A. Keyes M.B.A.CFO & Executive VP · born 1971
- Dr. Geoff Oxnard M.D.Chief Medical Officer & Executive VP · born 1977
- Dr. Vincent Liptak J.D., M.B.A., Ph.D.General Counsel & Executive VP · born 1971
- Dr. Zachary F. Zimmerman M.D., Ph.D.Senior Vice President of Clinical Development
- Dr. Eugene Y. Rui Ph.D.Senior Vice President of Chemistry
- Dr. Z. Jesse Shao Ph.D., R.Ph.Senior Vice President of CMC
- Dr. Ashley Preston Ph.D.Senior VP and Head of Regulatory Affairs & Quality Assurance
- Dr. Antonio Garrido-Montalban Ph.D.Senior Vice President of Drug Substance